CSL stock trades at EUR 113.73 with AUD 88.0 billion market value

Published on 10/09/2026 at 16:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2026 revenue reached US$15.8 billion, up 1.50 percent. CSL stock costs EUR 113.73 on October 9, 2026 after EUR 112.28.

Key points in brief

CSL stock was trading at EUR 113.73 at Lang & Schwarz on October 9, 2026, up 1.29 percent from EUR 112.28.
CSL's ASX market capitalization was AUD 88.0 billion, while the stock remained 17.37 percent below its AUD 222.47 52-week high.
Fiscal 2026 revenue reached US$15.8 billion, up 1.50 percent from fiscal 2025, according to Simply Wall St.
CSL's 2026 annual general meeting is scheduled for October 27, 2026, according to the company.

CSL, AU000000CSL8, Illustration mit AI erstellt.

CSL Limited stock (ISIN AU000000CSL8) was trading at EUR 113.73 at Lang & Schwarz on October 9, 2026 at 4:34 p.m. CEST, up 1.29 percent versus the prior close of EUR 112.28. Its ASX market capitalization was AUD 88.0 billion on October 9, 2026.

Price sits below yearly high

On the Australian Securities Exchange, CSL last stood at AUD 183.84 on October 9, 2026 at 4:12 p.m. AEDT. The quote was 17.37 percent below the 52-week high of AUD 222.47 and above the 52-week low of AUD 90.00, placing the stock in the lower part of its annual range.

The primary-market valuation was 24.19 times earnings on October 9, 2026, while the trailing dividend yield was 0.02 percent. Those figures put CSL's market value well above the two Australian healthcare names used in the peer comparison below, although the companies have different business mixes.

Fiscal results set the baseline

Simply Wall St reports that CSL generated US$15.8 billion of revenue in fiscal 2026, up 1.50 percent from fiscal 2025. The same fiscal-year summary records a US$2.58 billion net loss and a US$5.35 loss per share, compared with a US$3.00 billion net profit and US$6.20 earnings per share in fiscal 2025.

The contrast between higher revenue and a large reported loss makes the valuation multiple less informative on its own. For market watchers, the October 9 price therefore provides a cleaner read on trading conditions than a single earnings ratio.

Comparison with peers

CSL: plus 1.29 percent, P/E 24.19, market capitalization AUD 88.0 billion
ResMed (ASX, AUD): plus 0.09 percent, P/E 22.08, market capitalization AUD 47.3 billion
Sonic Healthcare (ASX, AUD): minus 0.27 percent, P/E 15.16, market capitalization AUD 9.2 billion

Next date is October 27

CSL states that its 2026 annual general meeting will take place on October 27, 2026. Its investor page also identifies the fiscal 2026 results period as ending June 30, 2026, with the results webcast held on August 18, 2026.

For CSL stock, the immediate market picture combines a 1.29 percent daily gain in euros with a 17.37 percent gap to the ASX 52-week high. The next scheduled corporate date is the October 27 meeting.

Trading data and company details

CSL was trading at EUR 113.73 at Lang & Schwarz on October 9, 2026 at 4:34 p.m. CEST, versus the EUR 112.28 prior close from October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of CSL stock.